Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP1 | O94782 | 15/20 | 0.41 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.34 |
| ▸ | WDR48 | Q8TAF3 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29296052 | 0.91 | USP1 (0.40) | USP1RPS6KA3 | |
| SCHEMBL29296065 | 0.87 | USP1 (0.34) | USP1RPS6KA3WDR48HDAC1HDAC6 | |
| SCHEMBL27088186 | 0.81 | USP1 (0.45) | USP1 | |
| SCHEMBL30693863 | 0.81 | USP1 (0.45) | USP1 | |
| SCHEMBL30032008 | 0.79 | USP1 (0.33) | USP1 | |
| SCHEMBL27088164 | 0.79 | USP1 (0.33) | USP1 | |
| SCHEMBL30032070 | 0.77 | USP1 (0.39) | USP1WDR48 | |
| SCHEMBL27088229 | 0.77 | USP1 (0.39) | USP1WDR48 | |
| SCHEMBL25199204 | 0.76 | USP1 (0.40) | USP1WDR48 | |
| SCHEMBL30443348 | 0.76 | USP1 (0.40) | USP1WDR48 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | HAINAN SIMCERE ZAIMING PHARMACEUTICAL CO., LTD. (CN) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240226107-A1 | UBIQUITIN-SPECIFIC PROTEASE 1 (USP1) INHIBITOR | USP1, USP2, USP3 | USP1 1/4885RPS6KA3 2390/4885WDR48 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.